Ilomedin (Iloprost Trometamol)

Iloprost Trometamol selectively binds to the IP (prostacyclin) receptor on vascular smooth‑muscle cells, raising intracellular cyclic AMP. This leads to vasodilation of pulmonary and systemic arteries, inhibition of platelet aggregation, and improved endothelial function, which together reduce pulmonary arterial pressure.

The dosing regimen for Ilomedin is individualized by the prescribing physician. It is typically started at a low infusion rate and titrated upward based on clinical response and tolerability, with adjustments made according to blood pressure and symptom control.

Safety data for Ilomedin during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ilomedin (iloprost) is a prostacyclin analog similar to epoprostenol and treprostinil. Compared with epoprostenol, iloprost has a longer half‑life and can be administered via intermittent IV infusion rather than continuous infusion, offering more flexibility. All share vasodilatory and antiplatelet effects but differ in administration routes and stability.

Ilomedin must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. The solution should be kept in its original container until use, and any unused portion should be discarded according to local regulations.

Ilomedin is supplied as a sterile solution for injection and is administered intravenously. It is usually given as a continuous infusion over a defined period, with the rate adjusted by the clinician based on patient response and tolerability.

The most serious adverse events include severe hypotension, pulmonary edema, and significant bleeding. Patients should be monitored closely for sudden drops in blood pressure, respiratory distress, or signs of hemorrhage during and after infusion.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, and it should be avoided in individuals with recent major bleeding, uncontrolled severe heart failure, or severe hypotension.